To overcome these limitations, Antengene developed ATG-201, a “2+1” CD19 x CD3 TCE, which was evaluated in a series of in ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Drug discovery efforts have expanded beyond the traditional approaches of small molecules and antibodies to include cells. This article explores the use of microfluidic methods for high-throughput ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Food products contaminated with fungicides and mycotoxins further threaten human health as the mixtures cause synergistic ...

To treat glioblastoma, Purdue researchers are developing antibody-based immunotherapies to improve the recruitment and ...

In lab tests, Magnolia essential oil disrupted harmful bacteria and neutralized free radicals, showing promise as a natural ...

Gain expert insights in this interview on achieving transfection success. Explore proven strategies to optimize your approach and enhance results.

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early ...